DCVC Bio
Venture capitalPalo Alto · Seed–Growth · 16 people tracked
Find your way into DCVC Bio
2,252 people in our graph share verified history with the DCVC Bio team — schools, employers, funds. One of them is your warm intro.
Investment thesis
DCVC Bio invests in founders marrying deep biological insight and engineering with large-scale computation to solve hard problems. Established in 2018, it backs foundational science and deep tech ventures across drug discovery (using synthetic biology, microfluidics, and machine learning to create novel therapies), agriculture (safer crop protection, reduced fertilizer use, renovated food systems), and bio-based alternative materials. The firm's team combines scientific expertise in genetics, chemistry, molecular biology, agriculture, industrial fermentation, and AI with decades of operational management experience, aiming to improve human health, make food production more sustainable, and slow climate change.
Source: firm website, verified Aug 24, 2026.
Team · 16 people
from the firm's website & curated
Founder mafia
2 people who came through DCVC Bio went on to found or lead other companies.
What they invest in
from 26 of 34 portfolio companiesBiotech ×21AI & Machine Learning ×12Deep Tech ×12Healthtech ×6Medical Devices ×5Climate Tech ×4AgTech ×3Cleantech ×2
HQs:United States×19Australia×1
Investments · 34 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 42024 · 12023 · 62022 · 32021 · 42016 · 121 dated
Fervo Energy develops next-generation geothermal technology using advanced drilling and sensing techniques to unlock carbon-free, 24/7 power generation in previously uneconomic locations.
CleantechClimate TechEnergyHouston, US
Tim Latimer(Founder & CEO)inJack Norbeck(Founder)in
BoardDavid Thomas Danielson(Director)inNicholas Walrod(Director)inIon Yadigaroglu(Director)
Co-investorsB Capital GroupB4 CapitalBaruch Future VenturesBeast VenturesBreakthrough Energy VenturesCarbon+14 more
.jpeg){kind=logo}
Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.
BiotechHealthtechSeattle, US
Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)
BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)
Board seatJohn Hamer· per SEC Form D
Co-investorsMPM BioImpactQiming Venture Partners USASoftBank GroupK2 HealthVenturesSoftBank Vision FundDCVC (Data Collective)
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsRA CapitalDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.British Business Bank+2 more
Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.
BiotechHealthtechLongevity
Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)
Co-investorsMPM BioImpactVersant VenturesLilly Asia VenturesDCVC (Data Collective)
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
BiotechData & InfrastructureEnterprise SoftwareMedia & EntertainmentDurham, US
Pieter Burger(Executive Officer, Director)inThomas Kaiser(Executive Officer, Director)in
BoardChristopher Meldrum(Executive Officer, Director)inDennis Langer(Director)
Board seatJohn Hamer· per SEC Form D
Elo develops plant-based food ingredients and technologies to enhance nutritional value, taste, and climate resilience in everyday foods.
AgTechBiotechClimate TechFoodTechNew MaterialsDurham, US
ToddMichele Fite(Executive Officer)inMatthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)inMatt DiLeo(Director)inPaul Boyer(Executive Officer)in
Board seatKiersten Stead· per SEC Form D
Co-investorsDCVC (Data Collective)Accelr8KdT VenturesNovo Holdings
Empirico is a San Diego-based clinical-stage biotech that uses human genetics data and computational methods to discover disease targets and develop siRNA and antibody therapeutics.
San Diego, US
Board seatJohn Hamer· per SEC Form D · $55.2M raise · filed Mar 2023
Co-investorsDCVC (Data Collective)
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Director)inMichael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)in
BoardThomas Grotkjaer(Director)
Board seatKiersten Stead· per SEC Form D
Co-investorsDCVC (Data Collective)Hemisphere Ventures LLCWireframe Ventures8VCAgFunderHumboldt+5 more
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US
Charles Fisher(Founder & CEO)inAaron Smith(Founder)in
Board seatJohn Hamer· per SEC Form D
Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Eisai Innovation, Inc.Flucas Ventures+5 more
AgZen develops real-time monitoring technology for crop spraying, analyzing droplet behavior to help growers and agricultural equipment manufacturers optimize application efficiency.
AgTechAI & Machine LearningFintechHardwareImpact & Social GoodMedia & Entertainment
Vishnu Jayaprakash(Founder)inKripa VaranasiinMaher Damak
Co-investorsAstanor VenturesMaterial ImpactDCVC (Data Collective)Syngenta Group Ventures
BiotechNewton, US
Katharine Yen(Executive Officer, Director)Kate Yen(Founder)inChristopher Guiffre(Executive Officer)
BoardAlon Lazarus(Director)Anna French(Director)inAlexandra Cantley(Director)in
Co-investorsDCVC (Data Collective)Apollo Health VenturesPolaris Partners
CH4 Global develops greenhouse gas mitigation solutions centered on Asparagopsis seaweed, producing feed supplements that reduce enteric methane emissions from cattle for the livestock and agriculture industries.
AgTechCleantechClimate TechFoodTech
Steve Meller(CEO, President & Co-Founder)in
Co-investorsCleveland AvenueDCVC (Data Collective)AgFunder
Creyon develops aptamer-delivered oligonucleotide therapeutics for targeted cell-specific delivery, including small interfering RNA and antisense oligonucleotides.
AI & Machine LearningBiotechDeep Tech
Matthew Levy(Co-founder)in
Co-investorsLux CapitalTenmile
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease.
AI & Machine LearningBiotechDeep Tech
Co-investorsBioBritDCVC (Data Collective)TenmileAlexandriaCasdin CapitalLux Capital
DCVC is a deep technology venture capital firm that invests in entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, robotics, space, biology, and defense.
AI & Machine LearningClimate TechDeep Tech
Matt Ocko(Founder and Managing Partner)inZachary Bogue(Founder and Managing Partner)Dr. John Hamer(Co-founder and Managing Partner, DCVC Bio)Dr. Kiersten Stead(Co-founder and Managing Partner, DCVC Bio)
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesMPM BioImpactRA CapitalDeerfield Management Company
Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics.
AI & Machine LearningBiotechDeep TechChicago, US
Geoffrey Duyk(CEO)inGeoffrey M. Duyk, M.D., Ph.D.(Chief Executive Officer)in
Co-investorsDCVC (Data Collective)InVivium CapitalPortal Innovations
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+2 more
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)
Co-investorsDCVC (Data Collective)Longwood FundNovo Holdings
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechNew York, US
Jeff Goater(Executive Officer, Director)inKim Seth(CEO)in
BoardTim Kutzkey(Executive Officer, Director, Promoter)in
Co-investorsDCVC (Data Collective)The Column GroupLux Capital
South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.
Daly City, US
Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)
BoardElizabeth Stanley(Director)
Co-investorsAlta PartnersCerity Partners Ventures5AM VenturesAlexandriaDCVC (Data Collective)
Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US
Brett Ewald(Chief Operating Officer, Founding Member)inAlyssa Levin(Chief Financial Officer)inPaul Grayson(Chief Executive Officer)in
Co-investors5AM VenturesFrazier Life Sciences
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesFrazier Healthcare PartnersWestlake Village BioPartners
Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.
BiotechHealthtechMedical DevicesSan Diego, US
Eric Murphy(Chief Executive Officer, Co-Founder, & Director)in
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Frazier Life SciencesLongwood FundNovartis Venture FundOrbiMed+2 more
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)Draper AssociatesIllumina VenturesPortal InnovationsWalder Ventures
Totus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Neil Dhawan, PhD(Co-Founder)Nassim Usman, PhD(CEO and President)
Co-investorsDCVC (Data Collective)Social Impact Capital
Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.
AI & Machine LearningBiotechDeep Tech
Co-investorsBlueYard CapitalJAZZ Venture PartnersARCH Venture PartnersInsight Partners
Verdant is a software platform that manages the full planning and permitting workflow for local government agencies, from resident inquiries through final commission votes.
AI & Machine LearningGovTechSan Francisco, US
Aidan Ng(Co-founder)inJason Yi(Co-Founder)in
Co-investorsY CombinatorAgFunderAutotech VenturesCavallo VenturesCleveland AvenueFuture Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Epsilon Holdings, Inc.Ascend Gene & Cell TherapiesBioPheroGreaterlongislandNewyorkerSolu Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
1 IPOs · 1 acquisitionsFervo EnergyNASDAQ: FRVOBioPheroacq. by FMC
Portfolio news
latest coverage across their companies
Sidewinder Therapeutics · techcrunch.com · Jul 30, 2026
Transcripta Bio · infotechlead.com · Jul 24, 2026
Alchemab Therapeutics · healthcaretoday.com · Jul 22, 2026
Fervo Energy · investing.com · Jul 17, 2026
Verdant · theinvestor.vn · Jul 16, 2026
Fable · twitter.com · Jul 1, 2026
nChroma Bio · contagionlive.com · Jun 25, 2026
Fund performance · per public LP disclosures
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| DCVC Bio II, L.P.LPs: Employees' Retirement System of Rhode Island | 2020 | — | 3.5% | 1.07x | 0.21x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has DCVC Bio made?
- DCVC Bio has 34 tracked investments, 2 of which have exited, including 6 dated in the last 24 months.
- What stage does DCVC Bio invest at?
- DCVC Bio invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does DCVC Bio focus on?
- DCVC Bio focuses on Advanced Manufacturing, AgTech, AI & Machine Learning, Biotech, Climate Tech, Cybersecurity, Deep Tech, Defense Tech, Energy, Fintech, FoodTech, InsurTech, Longevity, New Materials, Quantum Computing, Space Tech.
- Where is DCVC Bio located?
- DCVC Bio is headquartered in Palo Alto, US.
- Who does DCVC Bio co-invest with?
- DCVC Bio most often shares deals with DCVC (Data Collective), Astellas Venture Management LLC, Portal Innovations, among 25 tracked co-investors.
Images
Similar investors
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
The Business Development Bank of Canada (BDC) is a bank dedicated to Canadian entrepreneurs, providing financing and advisory services to small and medium-sized businesses across all industries and growth stages.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Radix Ventures is a venture capital firm founded in 2024 by entrepreneurs and tech investors, focused on empowering deep tech innovators across Europe, particularly Central and Eastern Europe.